Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Jazz Pharmaceuticals announced that the Phase 3 LAGOON trial for Zepzelca in second-line small cell lung cancer failed to meet its primary endpoint of overall survival. Zepzelca monotherapy showed a median OS of 8.7 months versus 10.7 months for the control arm (HR 1.19), while the combination with irinotecan showed 10.9 months versus 10.7 months (HR 0.90), neither achieving statistical significance.
Key figures
- Drug Name
- Zepzelca (lurbinectedin)
- Phase Of Trial
- Phase 3
- Median os combo
- 10.9 months
- Trial enrollment
- 724
- Median os control
- 10.7 months
- Hr combo vs control
- 0.902
- Median os monotherapy
- 8.7 months
- Hr monotherapy vs control
- 1.190
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.